'Fully Engaged' docs more open to influence

Share this article:
A new study measuring physician engagement levels with reps found that prescribing behavior is influenced significantly by social chemistry.

The study, conducted by PeopleMetrics Rx, categorized physicians at four levels of engagement – “Fully Engaged,” “Engaged,” “On the Fence” and “Disengaged”–during atypical antipsychotic sales details. 

According to the study, the most effective reps formed personal relationships with physicians. Full engagement describes physicians that “enjoy the relationship [with a rep], would go out of their way to continue to meet with their sales rep, actively recommend the rep to others, and, given the choice, would keep their rep assigned to their practice.”

Study data suggests that fully engaged physicians prescribing a given product for 30% of patients, will increase scripts to 37% over six months. Disengaged physicians prescribing a product for 19% of patients will increase scripts to 20% over six months, the study found.

Additionally, fully engaged physicians spend more than twice as long speaking with reps per visit and meet with them twice as frequently as disengaged physicians.

"Measuring the emotional connection sales reps develop with their physicians is not typically monitored in standard sales force effectiveness research...yet we find that this emotional dimension is key in understanding physicians' perceptions toward their reps and the pharmaceutical company as a whole," said Gary White, EVP, PeopleMetrics Rx and lead researcher on the study, in a statement.

The study, titled Driving Physician Engagement and Productivity in Pharmaceutical Sales, included sales detailing for the following products: Bristol-Myers Squibb's Abilify; Pfizer's Geodon; Invega's Risperdal; AstraZeneca's Seroquel; and Eli Lilly's Zyprexa.
Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...